✦ LIBER ✦

PSS5 Bevacizumab Versus Ranibizumab for Age-Related Macular Degeneration (AMD): A Budget Impact Analysis

✍ Scribed by Zimmermann, I.; Schneiders, R.E.; Mosca, M.; Alexandre, R.F.; do Nascimento, J.M.; Gadelha, C.A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-utility analysis of bevacizumab ver

✍ Jignesh J. Patel; Margaret A.S. Mendes; Mark Bounthavong; Melissa L.D. Christoph 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

Intravitreal Bevacizumab and Ranibizumab

✍ Donald S. Fong; Peter Custis; Jennifer Howes; Jin-Wen Hsu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 421 KB

PSS11 Ranibizumab and Bevacizumab for th

✍ Martinez Ferez, I.M.; Flores Moreno, S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTA

✍ LY Lu; W McGhan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Ranibizumab versus Bevacizumab for Neova

✍ Kodjikian, Laurent; Souied, Eric H.; Mimoun, Gérard; Mauget-Faÿsse, Martine; Beh 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 770 KB

Comparing Treatment Patterns And Efficac

✍ Jiang, S.; Park, C.; Barner, J.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB